This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental material
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Paeshuyse, J.
Right arrow Articles by Neyts, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paeshuyse, J.
Right arrow Articles by Neyts, J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2008, p. 3433-3437, Vol. 52, No. 9
0066-4804/08/$08.00+0     doi:10.1128/AAC.01534-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Comparative In Vitro Anti-Hepatitis C Virus Activities of a Selected Series of Polymerase, Protease, and Helicase Inhibitors{triangledown} ,{dagger}

Jan Paeshuyse,1 Inge Vliegen,1 Lotte Coelmont,1 Pieter Leyssen,1 Oriana Tabarrini,3 Piet Herdewijn,1 Harald Mittendorfer,2 Johnny Easmon,2 Violetta Cecchetti,3 Ralf Bartenschlager,4 Gerhard Puerstinger,2 and Johan Neyts1*

Rega Institute for Medical Research, K.U. Leuven, 3000 Leuven, Belgium,1 Department of Pharmaceutical Chemistry, Institute of Pharmacy, University of Innsbruck, Innsbruck, Austria,2 Dipartimento di Chimica e Tecnologia del Farmaco, Università degli Studi di Perugia, Perugia, Italy,3 Department of Molecular Virology, University of Heidelberg, 69120 Heidelberg, Germany4

Received 28 November 2007/ Returned for modification 16 January 2008/ Accepted 8 July 2008

We report here a comparative study of the anti-hepatitis C virus (HCV) activities of selected (i) nucleoside polymerase, (ii) nonnucleoside polymerase, (iii) {alpha},{gamma}-diketo acid polymerase, (iv) NS3 protease, and (v) helicase inhibitors, as well as (vi) cyclophilin binding molecules and (vii) alpha 2b interferon in four different HCV genotype 1b replicon systems.

* Corresponding author. Mailing address: Rega Institute for Medical Research, Minderbroedersstraat 10, B-3000 Leuven, Belgium. Phone: 32-16-337341. Fax: 32-16-337340. E-mail: johan.neyts{at}rega.kuleuven.be

{triangledown} Published ahead of print on 14 July 2008.

{dagger} Supplemental material for this article may be found at http://aac.asm.org/.

Antimicrobial Agents and Chemotherapy, September 2008, p. 3433-3437, Vol. 52, No. 9
0066-4804/08/$08.00+0     doi:10.1128/AAC.01534-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Lin, T.-I, Lenz, O., Fanning, G., Verbinnen, T., Delouvroy, F., Scholliers, A., Vermeiren, K., Rosenquist, A., Edlund, M., Samuelsson, B., Vrang, L., de Kock, H., Wigerinck, P., Raboisson, P., Simmen, K. (2009). In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor. Antimicrob. Agents Chemother. 53: 1377-1385 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»